Australian antiviral drug development company, Island Pharmaceuticals (ASX:ILA), has signed an agreement to acquire the galidesivir antiviral program from US-based BioCryst Pharmaceuticals.

Latest Video
New Stories
-
Is this the missing link in pharma engagement strategies?
July 9, 2025 - - Latest News -
Stakeholders welcome medicinal cannabis crackdown
July 9, 2025 - - Latest News -
Might Australia be just a little hypocritical on pharmaceutical tariffs?
July 9, 2025 - - Latest News -
This debate over US tariffs might be the dumbest in PBS history
July 9, 2025 - - Latest News -
Island expands portfolio with the acquisition of antiviral
July 9, 2025 - - Australian Biotech -
Health spending under increasing pressure, as department looks to offsets
July 9, 2025 - - Latest News -
AusBiotech welcomes 27 new members in first half of 2025
July 9, 2025 - - Latest News